Introduction {#sec1}
============

An estimated 6 million bone fractures occur yearly in North America, with a risk factor ranging between 150 and 250 per 100,000 \[[@bib1]\]. Fracture risk augments with age in the general population and correlates with bone mineral density (BMD) and osteopenia incidence \[[@bib2]\]. Moreover, developmental skeletal disorders such as osteogenesis imperfecta can dramatically increase these odds \[[@bib3]\]. Bone disorders, whether metabolic or developmental, significantly increase the rate of complication such as delayed union, malunion, nonunion or refracture \[[@bib2],[@bib4]\]. There thus exists an unmet clinical need to ameliorate fracture management strategies, especially for at-risk populations.

Bone fracture healing involves a series of tightly regulated events \[[@bib5]\]. It begins with the formation of a haematoma at the fracture site towards which immune and precursor cells migrate, proliferate and differentiate. The formation of a fibrocartilaginous callus then follows, stabilizing the fracture and progressively mineralizing through endochondral and intramembranous ossification. The mineralized callus is subsequently remodelled into true lamellar bone, thus restoring structure and function to the affected limb. Alterations in this process extend hospitalization time, augment risk of complication and significantly impair quality of life in affected patients \[[@bib6]\]. Numerous risk factors ranging from genetics, pharmaceutical treatments and lifestyle have all been shown to impact fracture repair outcome \[[@bib7]\].

Although it is generally accepted that vitamin D deficiency at the time of fracture increases the risk of complication \[[@bib8]\], the beneficial effects of vitamin D supplementation during fracture repair remain debated \[[@bib9]\]. Several confounding factors exist, namely the high number of vitamin D metabolites, coadministration of calcium supplements, vitamin D status and age of the tested cohorts, as well as lack of focus on time points. Over two decades ago, the 24R,25-dihydroxyvitamin D~3~ \[24,25(OH)~2~D~3~\] metabolite has been suggested to participate in the fracture repair process in chicks \[[@bib10]\]. However, this correlation remains equivocal in human beings as 24,25(OH)~2~D~3~ levels remain stable throughout the healing process, at least in older patients \[[@bib11]\].

Recently, our team has shown that *Cyp24a1*-null mice, unable to produce 24,25(OH)~2~D~3~, display impaired callus formation during the endochondral phase of fracture repair \[[@bib12]\]. The 24,25(OH)~2~D~3~ metabolite acted by binding to the Tram-Lag1-CLN8 (TLC) domain containing 3B isoform 2 (TLCD3B2, new Human Genome Organization Gene Nomenclature Committee name and symbol for FAM57B2) and inducing synthesis of lactosylceramide (LacCer) by TLCD3B2. Cartilage-specific deletion of *Tlcd3b* phenocopied the impaired fracture repair observed in *Cyp24a1*-null mice, and the physiological relevance of the signalling cascade was further highlighted by rescue experiments. Subcutaneous administration of 24,25(OH)~2~D~3~ or LacCer restored both callus size and mechanical properties in *Cyp24a1*-null mice, whereas cartilage-specific deletion of *Tlcd3b* could only be rescued with exogenous LacCer supplementation \[[@bib12]\]. In this follow-up study, we aimed at testing the safety and efficacy of these two compounds in ameliorating fracture healing of nongenetically modified mice, and to identify a time range for efficient intervention.

Materials and methods {#sec2}
=====================

Animals {#sec2.1}
-------

Ten-week-old female mice from the C57BL/6 strain were ordered from Charles River (Senneville, QC, Canada) and left in quarantine to acclimate until 12 weeks of age. All animals were housed five per cages at 25 °C with a 12 h dark/12 h light cycle and *ad libitum* access to food and water.

All standard operating procedures were approved by the IACUC of Shriners Hospitals for Children -- Canada (AUP 4138), as part of the McGill University animal ethics and care program, and followed the guidelines of the Canadian Council on Animal Care.

Intramedullary rodded tibial osteotomy {#sec2.2}
--------------------------------------

The surgical procedure was performed as described in Martineau et al. \[[@bib12]\]. Briefly, mice under general isoflurane anaesthesia had an incision made above the right knee to free the patellar ligament from lateral tissue. A 26G needle was gently pushed through the tibial plateau allowing insertion of a 25G spinal needle wire guide under the patellar ligament down the medullary canal. The needle was pulled out, the wire guide was bent 90°, cut at the tibial plateau and secured by a mattress suture on either side of the patellar ligament. The tibial shaft was exposed and cut using micro scissors about 2--3 mm above the tibiofibular junction. Topical analgesics were applied at the wound site, then the skin was sutured. Carprofen was provided at the time of surgery and for the following 48 h postosteotomy. After isoflurane general anaesthesia and exsanguination through cardiac puncture, mice were euthanized by cervical dislocation on Days 10, 12, 15, 18 and 21. Serum and bones were harvested for analysis for each time point.

LacCer and 24,25(OH)~2~D~3~ treatment {#sec2.3}
-------------------------------------

Seventy-two hours postosteotomy, mice were injected subcutaneously daily with either 24,25(OH)~2~D~3~ (6.7 μg/kg daily in 50 μL propylene glycol with trace ethanol for vitamin D metabolite solubility); C18-LacCer (50 μg/kg daily in 50 μL propylene glycol with trace dimethyl sulfoxide (DMSO) for solubility) or the propylene glycol with trace ethanol or DMSO vehicle until sacrifice, as described previously \[[@bib12]\].

Serum biochemistry {#sec2.4}
------------------

After harvest of whole blood through cardiac puncture, serum was isolated by centrifugation (20 min at 2000*g*, 4 °C), aliquoted and frozen at −80 °C until analysis. Serum biochemistry for liver and kidney function (aspartate transaminase \[AST\], alanine transaminase \[ALT\], gamma glutamyltransferase \[GGT\], total bilirubin, glucose, albumin, total protein, creatine kinase \[CK\], blood urea nitrogen and creatinine) was outsourced to the McGill Comparative Medicine Animal Resources Centre; samples were streamlined through the Vitros 250 Chemistry System (Ortho Clinical Diagnostics, Markham, ON, Canada). Alkaline phosphatase (ALP) was measured using the QuantiChrom Alkaline Phosphatase Assay Kit (BioAssay Systems, Hayward, CA, USA); calcium and phosphorus were measured with the SEKURE chemistry calcium and phosphorus kits (Sekisui Diagnostics, Kent, United Kingdom) and cFGF-23 was measured with the ELISA Mouse/Rat cleaved FGF-23 Kit (Quidel Corporation, Athens, OH, USA). Bone formation and resorption markers, osteocalcin (OCN; Immunotopics, San Clemente, CA, USA) and carboxy-terminal collagen crosslinks (CTX; Immunodiagnostic Systems, East Boldon, United Kingdom) were measured using ELISA kits.

Vitamin D metabolites were assayed by liquid chromatography--tandem mass spectrometry (LC-MS/MS) following 4-\[2-(3,4-Dihydro-6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl\]-3H-1,2,4-triazole-3,5(4H)-dione (DMEQ-TAD) derivatization as described previously \[[@bib13]\]. For analysis of 25(OH)D~3~, 24,25(OH)~2~D~3~ and 25(OH)D~3~-26,23-lactone, 25 μL volumes of mouse serum and calibrators were spiked with internal standards and diluted to 300 μL with water. Proteins were precipitated by sequentially adding 100 μL of 0.1 M HCl, 150 μL 0.2 M zinc sulphate, and 450 μL methanol, with vortexing after the addition of each component. Tubes were centrifuged and supernatants were extracted with 700 μL of methyl tertiary butyl ether and 700 μL hexane, and vortexed. For analysis of 1,25(OH)~2~D~3~ and 1,24,25(OH)~3~D~3~, 125 μL volumes of mouse serum and calibrators were spiked with internal standards, and extracted with 100 μL of anti-1,25(OH)~2~D~3~ antibody slurry (Immundiagnostik AG, Bensheim, Germany) for 2 h at room temperature by end-over-end rotation. Using centrifugation, the slurry was isolated and rinsed four times with 400 μL of water, and vitamin D metabolites were eluted with 400 μL of ethanol. Dried residues from both extraction platforms were derivatized by addition of 0.1 mg/mL DMEQ-TAD dissolved in ethyl acetate for 30 min at room temperature in the dark and then a second time for 60 min. The reaction was stopped by addition of ethanol, and the samples were dried and redissolved in a 60:40 methanol/water running buffer. LC-MS/MS analysis was performed using an Acquity UPLC connected in-line with a Xevo TQ-S mass spectrometer in electrospray-positive mode (Waters Corporation, Milford, MA, USA). Chromatographic separations were achieved using a BEH-phenyl ultra-performance LC (UPLC) column (1.7 μm, 2.1 × 50 mm) (Waters) for 25(OH)D~3~ analysis, or a Cortecs C18^+^ UPLC column (2.7 μm, 2.1 × 100 mm) (Waters) for 1,25(OH)~2~D~3~ analysis, using a methanol--water--based gradient solvent system as previously described \[[@bib13]\].

Microcomputed tomography {#sec2.5}
------------------------

Calluses and contralateral tibiae destined to microcomputed tomography (microCT) analysis were harvested in phosphate-buffered saline (PBS), scanned with a model 1272 SkyScan microCT system (Bruker SkyScan, Kontich, Belgium) at 65 kV, 142 μAmp, 5 μm resolution and a 0.5° rotation using a 0.5-mm aluminium filter, and frozen at −20 °C until three-point bending tests (3PBTs). Raw data sets were reconstructed with InstaRecon software (Bruker SkyScan) and analyzed with CTAn software (Bruker SkyScan). Volumes of interest consisted of 400 slices (2 mm thick) above and below the osteotomy site, for a total volume of 4 mm^3^, and used to obtain the average callus area values used to normalize the 3PBTs. Volumetric BMD (vBMD) was evaluated in callus tissue by comparing to hydroxyapatite standard rods (Bruker SkyScan).

3PBTs {#sec2.6}
-----

For the 3PBTs, contralateral and callus tibiae were thawed overnight at room temperature and tested for mechanical properties using an Instron model 5943 single-column table frame machine (Instron, Norwood, MA, USA). A load-sensing cell was applied on the widest part of the callus, or 2--3 mm above the tibiofibular junction in the case of intact tibiae, which were held by holders set 6 mm apart. The raw output used for comparison was stiffness (N/mm), maximum load (N) and load at yield (N), which were further normalized to elastic modulus (MPa), ultimate strength (MPa) and strength at yield (MPa) using the callus area of the widest part of the callus as evaluated through microCT.

Histology {#sec2.7}
---------

Bones destined to histology and immunohistochemistry were harvested in 70% ethanol--1% glycerol and stored at −20 °C until processing. Bones were sequentially dehydrated at 4 °C and infiltrated with low-temperature polymerizing methylmethacrylate (MMA) solutions I, II and III containing, respectively, 0%, 4% and 8% benzoyl peroxide as described by Erben \[[@bib14]\]. Bones were embedded in MMA solution III supplemented with 0.4% 4-N,N,N,N-trimethylaniline (MilliporeSigma, Oakville, ON, Canada) and left to polymerize at −20 °C for 3 days under N~2~(g) atmosphere. Blocks were sectioned at 5 μm thickness using a rotary microtome equipped with a tungsten blade (Leica Microsystems, Concord, ON, Canada), stretched onto poly-[l]{.smallcaps}-lysine--coated superfrost slides, stacked with plastic clamps, and left to dry overnight at room temperature. For staining, sections were deplastified in xylene (1 h), ethylene glycol monoethyl ether acetate (1 h), then rehydrated from ethanol to water and stained with Alcian blue H&E Y-orange G trichrome. Images were taken using a Leica DMR microscope (Leica Microsystems) connected to a digital DP70 camera (Olympus Corporation, Tokyo, Japan). Image area measurements of Alcian blue H&E Y-orange G trichrome-stained sections were performed using ImageJ as described in the figure legend.

Immunohistochemistry {#sec2.8}
--------------------

Sections were deplastified and rehydrated as stated above, then blocked and permeabilized overnight at 4 °C in PBS containing 10% fetal bovine serum (Invitrogen, Thermo Fisher Scientific, Saint-Laurent, QC, Canada) and 0.1% Triton-X100 (Sigma-Aldrich, Oakville, ON, Canada). After rinsing for 3 × 10 min in PBS, the sections were incubated for 1 h at room temperature with the rabbit anti-TLCD3B polyclonal antibody from Biorbyt (\#orb183613, San Francisco, CA, USA) diluted 1:150 in PBS containing 10% normal rabbit serum (Invitrogen) and 0.1% Triton-X100. Sections were rinsed 3 × 10 min in PBS, then incubated 1 h at room temperature with goat anti-rabbit secondary IgG coupled to Alexa 594 (Invitrogen) diluted 1:1000 in PBS containing 10% normal goat serum and 0.1% Triton-X100. Sections were rinsed 3 × 10 min in PBS, mounted with ProLong Gold with DAPI (Invitrogen) then dried overnight at room temperature. Images were taken using a Leica DMR microscope (Leica Microsystems) connected to a digital PhotoFluor LM75 fluorescent camera (89 North, Williston, VT, USA). Cell counting of TLCD3B-immunostained sections was performed with ImageJ as mentioned in the figure legend.

Statistics {#sec2.9}
----------

All graphs and analyses were performed with the Prism 5 software (GraphPad, La Jolla, CA, USA). When applicable, normality of data distribution was assessed using the D\'Agostino-Pearson test. Student\'s *t* tests were applied when comparing two groups, or a two-way analysis of variance was applied when comparing three or more groups together, followed by either a Dunnett\'s post-test (when comparing all groups to a single control group) or a Bonferroni\'s post-test (when comparing all groups among each other). Strength of association was evaluated using the Spearman rank-order coefficient (r~S~). Statistical significance was set at a *p* value of 0.05 or below.

Results {#sec3}
=======

We recently reported that 24,25(OH)~2~D~3~ or LacCer treatment restores callus size and mechanical properties of healing bones in *Cyp24a1*-null mice \[[@bib12]\]. To assess the safety of these molecules, test the efficacy of the compounds for bone healing in nongenetically modified mice and narrow down the time range at which the TLCD3B2 protein acts during fracture repair, we treated 12-week-old, osteotomized C57Bl6 female mice with each compound for up to 21 days postosteotomy. Control cohorts were injected with the corresponding vehicle.

Kidney and liver function {#sec3.1}
-------------------------

A blood biochemistry panel was performed at each time point for either treatment to observe liver and kidney function. For treatment with either 24,25(OH)~2~D~3~ ([Table 1](#tbl1){ref-type="table"}) or LacCer ([Table 2](#tbl2){ref-type="table"}), total protein, albumin-to-globulin ratio, blood urea nitrogen, total bilirubin, ALT, AST, GGT and CK were all within normal ranges. Inexplicably, the 24,25(OH)~2~D~3~ treatment significantly reduced CK levels on Day 18 postosteotomy, but concentrations returned to vehicle values on Day 21.Table 1Blood biochemistry values in 12-week-old vehicle- or 24,25D~3~-treated female C57BL/6 mice 10--21 days postosteotomy.Table 1TreatmentVehicle24,25(OH)~2~D~3~Day10121518211012151821**Total protein** (33--66 g/L)39.7 ± 0.440.5 ± 0.642.8 ± 1.141.5 ± 0.343.2 ± 0.540.3 ± 0.440.8 ± 0.742.7 ± 1.143.2 ± 1.341.0 ± 0.4**Albumin** (25--48 g/L)20.2 ± 0.520.3 ± 0.522.2 ± 0.721.5 ± 0.221.7 ± 0.720.8 ± 0.220.5 ± 0.722.2 ± 0.722.5 ± 0.921.0 ± 0.3**AGR** (0.8--1.4)1.05 ± 0.041.02 ± 0.031.08 ± 0.031.08 ± 0.031.02 ± 0.061.08 ± 0.021.05 ± 0.041.10 ± 0.061.05 ± 0.021.07 ± 0.04**Glucose** (5--10.7 mmol/L)15.2 ± 1.015.4 ± 0.716.4 ± 0.617.7 ± 0.515.1 ± 0.716.5 ± 0.516.2 ± 1.214.4 ± 0.614.0 ± 1.315.3 ± 0.5**BUN** (6.4--10.4 mmol/L)7.10 ± 0.367.40 ± 0.308.30 ± 0.477.58 ± 0.167.93 ± 0.457.45 ± 0.267.57 ± 0.368.23 ± 0.386.07 ± 0.457.95 ± 0.25**Creatinine** (18--71 pmol/L)13.0 ± 0.013.0 ± 0.013.0 ± 0.013.0 ± 0.013.0 ± 0.013.0 ± 0.014.2 ± 1.013.0 ± 0.013.0 ± 0.013.0 ± 0.0**Tot. bil.** (2--15 pmol/L)3.00 ± 0.262.83 ± 0.173.28 ± 0.523.83 ± 0.313.83 ± 0.313.67 ± 0.493.50 ± 0.224.45 ± 1.206.33 ± 2.743.50 ± 0.22**ALT** (28--132 U/L)42.7 ± 0.941.0 ± 1.146.2 ± 1.249.8 ± 8.243.5 ± 1.553.8 ± 9.441.8 ± 4.143.5 ± 1.239.7 ± 1.242.5 ± 0.4**AST** (59--247 U/L)73.8 ± 2.481.8 ± 6.280.5 ± 4.084.7 ± 11.385.3 ± 9.297.0 ± 13.587.5 ± 8.687.0 ± 4.778.2 ± 4.880.8 ± 4.6**GGT** (0 U/L)10 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010.5 ± 0.510 ± 0**CK** (68--1070 U/L)654.8 ± 157.31088.0 ± 132.2913.0 ± 41.8847.5 ± 146.3313.3 ± 92.9677.5 ± 76.8916.3 ± 78.01064.2 ± 190.7**254.5** ± **66.8**[a](#tbl1fna){ref-type="table-fn"}385.2 ± 49.9**OCN** (ng/mL)102.7 ± 11.9NA156.4 ± 24.4184.0 ± 12.0108.5 ± 15.9126.3 ± 6.6NA173.3 ± 18.0**109.4** ± **20.4**[a](#tbl1fna){ref-type="table-fn"}155.8 ± 16.1**CTX** (ng/mL)18.5 ± 1.8NA17.8 ± 0.823.1 ± 1.717.2 ± 1.717.4 ± 1.2NA18.1 ± 1.323.3 ± 2.618.8 ± 0.9[^1][^2][^3]Table 2Blood biochemistry values in 12-week-old vehicle- or LacCer-treated female C57BL/6 mice 10--21 days postosteotomy.Table 2TreatmentVehicleLacCerDay10121518211012151821**Total protein** (33--66 g/L)41.5 ± 1.242.8 ± 1.142.0 ± 0.442.0 ± 0.642.5 ± 1.040.7 ± 0.341.8 ± 0.640.2 ± 0.442.2 ± 0.842.8 ± 0.5**Albumin** (25--48 g/L)21.5 ± 0.822.3 ± 0.821.8 ± 0.421.7 ± 0.222.7 ± 0.621.2 ± 0.721.7 ± 0.320.7 ± 0.322.2 ± 0.422.8 ± 0.3**AGR** (0.8--1.4)1.07 ± 0.021.05 ± 0.031.08 ± 0.031.07 ± 0.021.12 ± 0.031.10 ± 0.061.08 ± 0.021.10 ± 0.031.10 ± 0.001.15 ± 0.02**Glucose** (5--10.7 mmol/L)11.4 ± 1.113.1 ± 1.113.6 ± 0.513.6 ± 0.510.6 ± 0.813.5 ± 0.513.6 ± 0.511.7 ± 0.611.1 ± 1.413.5 ± 1.3**BUN** (6.4--10.4 mmol/L)7.08 ± 0.506.55 ± 0.227.1 5 ± 0.437.42 ± 0.406.97 ± 0.387.57 ± 0.296.27 ± 0.307.25 ± 0.228.90 ± 0.216.80 ± 0.22**Creatinine** (18--71 pmol/L)13 ± 013 ± 013 ± 013 ± 013 ± 013 ± 013 ± 013 ± 013 ± 013 ± 0**Tot. bil.** (2--15 pmol/L)3.17 ± 0.315.17 ± 1.803.62 ± 0.463.33 ± 0.212.67 ± 0.333.17 ± 0.313.50 ± 0.342.83 ± 0.313.17 ± 0.313.83 ± 0.48**ALT** (28--132 U/L)46.2 ± 1.744.3 ± 1.840.3 ± 1.144.3 ± 1.046.7 ± 0.744.5 ± 0.839.0 ± 0.944.5 ± 1.943.8 ± 1.043.8 ± 2.0**AST** (59--247 U/L)77.0 ± 4.184.5 ± 5.971.3 ± 2.079.5 ± 3.9105.5 ± 14.576.8 ± 5.284.2 ± 9.281.8 ± 8.477.3 ± 6.871.7 ± 6.4**GGT** (0 U/L)10 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010 ± 010 ± 0**CK** (68--1070 U/L)645.7 ± 133.5483.8 ± 85.7736.3 ± 134.5751.8 ± 247.6581.0 ± 140.6587.0 ± 36.9466.0 ± 145.2419.0 ± 49.4974.0 ± 531.4529.3 ± 220.2**OCN** (ng/mL)123.9 ± 15.4NA112.3 ± 6.8139.9 ± 6.9135.2 ± 18.9139.7 ± 21.9NA142.6 ± 8.7110.0 ± 9.3120.4 ± 17.9**CTX** (ng/mL)20.7 ± 1.7NA18.7 ± 1.421.5 ± 1.313.8 ± 1.320.5 ± 1.6NA21.7 ± 1.717.7 ± 1.210.6 ± 0.9[^4][^5]

Serum albumin and creatinine were found to be below reference values in all mice at every time point. However, glucose remained slightly above normal ranges, presumably due to increased metabolic demand during fracture repair \[[@bib15]\]. Overall, no parameter reached a critical value at any time point for either treatment.

Mineral homeostasis and bone turnover {#sec3.2}
-------------------------------------

Total ALP showed an increasing trend on Days 18 and 21 postosteotomy for both 24,25(OH)~2~D~3~ ([Fig. 1](#fig1){ref-type="fig"}A) and LacCer ([Fig. 1](#fig1){ref-type="fig"}E) supplementation, and this increase was statistically significant for the 24,25(OH)~2~D~3~ treatment on Day 18 compared to vehicle-treated mice. Serum calcium levels remained stable at the upper limit of the normal range throughout the experiment and were unaffected by either treatment ([Fig. 1](#fig1){ref-type="fig"}B and F). On the other hand, phosphorus levels ([Fig. 1](#fig1){ref-type="fig"}C and G) varied somewhat during fracture repair, sometimes exceeding the upper normal limit by a small margin, presumably linked to metabolic demand for mineralization \[[@bib16]\]. The 24,25(OH)~2~D~3~ treatment significantly influenced serum phosphorus levels on Days 18 and 21 postosteotomy, but LacCer had no significant impact. Circulating OCN levels, an index of bone formation, showed a similar trend as phosphorus in Day 18 samples from the 24,25(OH)~2~D~3~-treated group ([Table 1](#tbl1){ref-type="table"}). Serum levels of the bone resorption marker CTX were not significantly affected by either treatment ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}).Figure 1**Effect of 24,25(OH)~2~D~3~ or LacCer supplementation on mineral homeostasis during bone fracture repair in C57BL/6 mice**. Twelve-week-old female mice were subcutaneously injected with 24,25(OH)~2~D~3~ (6,7 μg/kg; A-D), LacCer (50 μg/kg; E-H) or propylene glycol vehicle (50 μL) from 3 to 21 days after osteotomy. The impact of either treatment on total serum ALP (A and E), calcaemia (B and F), phosphataemia (C and G) and c-terminal FGF23 (D and H) was monitored on Days 10, 12, 15, 18 and 21 post-OT. Shaded areas represent normal range for each parameter; not shown on graph, normal range for ALP extends to 209 U/L. ∗*p* \< 0.05; ∗∗*p* \< 0.01; ∗∗∗*p* \< 0.001 versus vehicle of corresponding time point; two-way analysis of variance (ANOVA) followed by Bonferroni post-test; *n* = 7 (ALP, Ca and P) or 8 (cFGF23). Data are mean ± standard error of the mean (SEM). 24,25D~3~ = 24,25(OH)~2~D~3~; ALP = alkaline phosphatase; LacCer = lactosylceramide; OT = osteotomy; Veh = vehicle.Figure 1

Because phosphorus levels were found to modestly vary during the fracture repair process, and somewhat after 24,25(OH)~2~D~3~ supplementation, c-terminal FGF23 (cFGF23) levels were assessed as it has been reported to be a marker of bone repair \[[@bib17]\]. Serum levels of cFGF23 remained within normal ranges and neither time nor treatment was found to exert a significant effect on this parameter ([Fig. 1](#fig1){ref-type="fig"}D and H). Along with unchanged calcium levels, these cFGF23 levels are indicative of normal parathyroid hormone (PTH) response and mineral homeostasis \[[@bib18]\].

Circulating vitamin D metabolites {#sec3.3}
---------------------------------

No difference was detected in levels of 25(OH)D~3~ ([Fig. 2](#fig2){ref-type="fig"}A and G), 25(OH)D~3~-26,23-lactone ([Fig. 2](#fig2){ref-type="fig"}C and I) nor 3-epi-25(OH)D~3~ ([Fig. 2](#fig2){ref-type="fig"}F and L) between either treatment or vehicle. As expected, subcutaneous injections of 24,25(OH)~2~D~3~ increased circulating levels of this metabolite about eight-fold throughout the treatment ([Fig. 2](#fig2){ref-type="fig"}B), but LacCer injections had no measurable impact on circulating levels of this metabolite ([Fig. 2](#fig2){ref-type="fig"}H). A significant decrease was observed for 1,25(OH)~2~D~3~ levels in 24,25(OH)~2~D~3~-injected mice ([Fig. 2](#fig2){ref-type="fig"}D), but not in LacCer-treated animals ([Fig. 2](#fig2){ref-type="fig"}J). Levels of 1,24,25(OH)~3~D~3~ were significantly increased in 24,25(OH)~2~D~3~-treated mice ([Fig. 2](#fig2){ref-type="fig"}E), suggesting 1α-hydroxylation of 24,25(OH)~2~D~3~ because the values exceeded that of 1,25(OH)~2~D~3~ levels alone. We previously showed that 1,24,25(OH)~3~D~3~ was produced in 24,25(OH)~2~D~3~-dosed *Cyp24a1*^−/−^ mice, confirming that 1,24,25(OH)~3~D~3~ can be produced directly from a 24,25(OH)~2~D~3~ dose via 1α-hydroxylation \[[@bib13]\]. We also detected the presence of 24-oxo-25(OH)D~3~, 24-oxo-23,25(OH)~2~D~3~ and calcioic acid in 24,25(OH)~2~D~3~-dosed animals at all time points postosteotomy (data not shown), revealing that 24,25(OH)~2~D~3~ is likely cleared from the animal in a parallel manner as previously described for 1,25(OH)~2~D~3~.Figure 2**Effect of 24,25(OH)~2~D~3~ or LacCer supplementation on circulating vitamin D metabolite levels during bone fracture repair in C57BL/6 mice**. Twelve-week-old female mice were subcutaneously injected with 24,25(OH)~2~D~3~ (6,7 μg/kg; A--F), LacCer (50 μg/kg; G--L) or propylene glycol vehicle (50 μL) from 3 to 21 days after osteotomy. Serum vitamin D metabolite levels were measured by liquid chromatography--tandem mass spectrometry (LC-MS/MS) after 4-\[2-(3,4-Dihydro-6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl\]-3H-1,2,4-triazole-3,5(4H)-dione (DMEQ-TAD) derivatization. The metabolites 25(OH)D~3~ (A and G); 24,25(OH)~2~D~3~ (B and H); 25(OH)D~3~-26,23-lactone (25(OH)D~3~-lactone; C and I); 1,25(OH)~2~D~3~ (D and J); 1,24,25(OH)~3~D~3~ (E and K) and 3-epi-25(OH)D~3~ (F and L) were monitored on Days 10, 12, 15, 18 and 21 post-OT. ∗∗*p* \< 0.01; ∗∗∗*p* \< 0.001 versus vehicle of corresponding time point, two-way ANOVA followed by Bonferroni post-test; *n* = 8. Data are mean ± SEM. 24,25D~3~ = 24,25(OH)~2~D~3~; LacCer = lactosylceramide; OT = osteotomy; Veh = vehicle.Figure 2

We observed relatively small variations in postfracture, time-dependent changes in ratios of circulating vitamin D metabolites, independently of treatment ([Fig. 3](#fig3){ref-type="fig"}). A significant decrease with time was measured for the 25(OH)D~3~:24,25(OH)~2~D~3~ ratio ([Fig. 3](#fig3){ref-type="fig"}A and D) as well as for the 25(OH)D~3~:25(OH)D~3~-26,23-lactone ratio ([Fig. 3](#fig3){ref-type="fig"}B and E). The 1,25(OH)~2~D~3~:25(OH)D~3~ ratio---an index of hydroxylation efficiency \[[@bib19]\]---was increased in the LacCer-treated cohort only.Figure 3**Effect of 24,25(OH)~2~D~3~ or LacCer supplementation on circulating vitamin D metabolite ratios and hydroxylation efficiency during bone fracture repair in C57BL/6 mice**. Data from [Fig. 2](#fig2){ref-type="fig"} were used to visualize ratios between 25(OH)D~3~ and 24,25(OH)~2~D~3~ (25D~3~:24,25D~3~; A and D), 25(OH)D~3~ and 25(OH)D~3~-26,23-lactone (25D~3~:25D~3~-lactone; B and E) and 1,25(OH)~2~D~3~ and 25(OH)D~3~ (1,25D~3~:25D~3~; C and F) after 24,25(OH)~2~D~3~ (A--C) or LacCer (D--F) treatment on Days 10, 12, 15, 18 and 21 post-OT. ∗*p* \< 0.05; ∗∗ *p* \< 0.01; ∗∗∗*p* \< 0.001 versus vehicle of corresponding time point, two-way ANOVA followed by Bonferroni post-test, *n* = 8. Data are mean ± SEM. G--I, impact of treatment on the strength of association between 25(OH)D~3~ and 24,25(OH)~2~D~3~ (G), 25(OH)D~3~-26,23-lactone (H), or 1,25(OH)~2~D~3~ (I) was evaluated using a nonparametric correlation analysis. ^a^*p* = 0.0311; ^b^*p* = 0.0246; ^c^*p* = 0.0024; ^d^*p* \< 0.0001, nonparametric Spearman correlation, *n* = 40 per group. Each circle represents one data point. 24,25D~3~ = 24,25(OH)~2~D~3~; LacCer = lactosylceramide; OT = osteotomy; Veh = vehicle.Figure 3

When plotting the different metabolite levels against the 25(OH)D~3~ metabolite concentrations from which they are derived ([Fig. 3](#fig3){ref-type="fig"}G--I), 24,25(OH)~2~D~3~ levels were found to positively correlate with 25(OH)~2~D~3~ in vehicle- and LacCer-treated groups (r~S~ for vehicle = 0.7523, *p* \< 0.0001; LacCer = 0.6817, *p* \< 0.0001, respectively), but not in 24,25(OH)~2~D~3~-treated groups (r~S~ = 0.1997, ns), indicative of a decoupling between these variables ([Fig. 3](#fig3){ref-type="fig"}G). A positive correlation between 25(OH)D~3~-26,23-lactone and 25(OH)D~3~ levels was observed in all three groups, but appeared weaker in LacCer-treated mice yet was stronger after 24,25(OH)~2~D~3~ treatment ([Fig. 3](#fig3){ref-type="fig"}H, r~S~ for vehicle = 0.5255, *p* \< 0.0001; 24,25D = 0.6909, *p* \< 0.0001; LacCer = 0.3413, *p* = 0.0311). The 24,25(OH)~2~D~3~ treatment somewhat strengthened the weak positive correlation between 1,25(OH)~2~D~3~ and 25(OH)D~3~ levels, whereas LacCer treatment disrupted it altogether ([Fig. 3](#fig3){ref-type="fig"}I, r~S~ for vehicle = 0.2511, *p* = 0.0246; 24,25D~3~ = 0.4675, *p* = 0.0024; LacCer = 0.2788, ns).

Callus structure and mechanical properties {#sec3.4}
------------------------------------------

During fracture repair, the callus tissue volume and bone volume peaked around Day 15 postosteotomy ([Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}), a time point corresponding to mineralization of the cartilaginous scaffold and the beginning of callus remodelling \[[@bib5]\]. The 24,25(OH)~2~D~3~ treatment ([Table 3](#tbl3){ref-type="table"}) significantly increased callus bone volume, bone surface, connectivity and connectivity density as well as mean polar moment of inertia versus vehicle-treated mice. vBMD was slightly reduced in Day 15 treated calluses ([Table 3](#tbl3){ref-type="table"}). LacCer treatment showed no measurable impact on callus size or structure ([Table 4](#tbl4){ref-type="table"}), but vBMD was increased by the treatment early in the sequence (Day 10; [Table 4](#tbl4){ref-type="table"}).Table 3Callus morphometric parameters in 12-week-old vehicle- or 24,25(OH)~2~D~3~-treated female C57BL/6 mice 10--21 days postosteotomy.Table 3TreatmentVehicle24,25(OH)~2~D~3~Day10 (9)12 (8)15 (8)18 (8)21 (8)10 (9)12 (8)15 (6)18 (9)21 (9)**TV** (mm^3^)8.61 ± 0.6611.08 ± 0.9414.82 ± 0.9511.64 ± 1.019.98 ± 1.487.93 ± 0.3410.21 ± 1.0517.80 ± 0.9411.12 ± 1.298.66 ± 0.94**BV** (mm^3^)1.57 ± 0.142.22 ± 0.142.94 ± 0.162.62 ± 0.201.56 ± 0.231.39 ± 0.091.98 ± 0.22**3.79** ± **0.22**[a](#tbl3fna){ref-type="table-fn"}2.42 ± 0.311.48 ± 0.16**BV/TV** (%)18.2 ± 0.420.4 ± 0.719.9 ± 0.322.7 ± 0.415.7 ± 0.617.4 ± 0.419.3 ± 0.821.4 ± 1.021.1 ± 1.117.0 ± 0.5**TS** (mm^2^)100.8 ± 4.1109.0 ± 5.0120.6 ± 3.3117.7 ± 4.298.7 ± 4.5101.5 ± 2.4106.1 ± 4.9123.9 ± 2.4110.8 ± 6.698.1 ± 3.7**BS** (mm^2^)250.6 ± 23.2336.7 ± 24.6460.0 ± 32.3366.9 ± 25.9209.9 ± 30.5230.7 ± 15.0310.0 ± 39.2**624.0** ± **38.2**[b](#tbl3fnb){ref-type="table-fn"}332.6 ± 43.6198.4 ± 21.3**iS** (mm^2^)10.8 ± 0.615.8 ± 0.521.4 ± 0.323.2 ± 1.019.2 ± 0.910.6 ± 0.614.1 ± 0.921.0 ± 0.622.5 ± 1.619.0 ± 1.3**TbPf** (mm^−1^)43.4 ± 1.138.8 ± 1.042.8 ± 1.037.1 ± 0.639.4 ± 0.846.8 ± 1.040.7 ± 1.645.1 ± 2.138.5 ± 1.538.3 ± 0.8**SMI** (unitless)1.63 ± 0.031.54 ± 0.021.65 ± 0.021.59 ± 0.031.75 ± 0.031.69 ± 0.021.57 ± 0.031.64 ± 0.061.68 ± 0.061.71 ± 0.03**Conn** (unitless)41391.3 ± 4408.355182.3 ± 4815.774944.9 ± 7681.250260.5 ± 3808.620015.8 ± 3361.339261.5 ± 3332.752601.5 ± 7869.6**119405.7** ± **13072.5**[c](#tbl3fnc){ref-type="table-fn"}41478.5 ± 6550.720318.2 ± 3407.8**ConnDen** (μm^−1^)0.59 ± 0.020.62 ± 0.020.62 ± 0.030.55 ± 0.030.25 ± 0.020.61 ± 0.030.63 ± 0.04**0.84** ± **0.08**[c](#tbl3fnc){ref-type="table-fn"}0.44 ± 0.040.29 ± 0.04**pMMI** (mm^4^)3.33 ± 0.384.51 ± 0.456.47 ± 0.574.86 ± 0.572.78 ± 0.562.99 ± 0.224.37 ± 0.73**8.92** ± **0.76**[a](#tbl3fna){ref-type="table-fn"}4.50 ± 0.712.56 ± 0.39**FD** (unitless)2.43 ± 0.022.51 ± 0.012.59 ± 0.012.56 ± 0.012.46 ± 0.032.40 ± 0.022.47 ± 0.022.64 ± 0.012.53 ± 0.042.44 ± 0.02**vBMD** (mg/mm^3^)1477 ± 0.0081482 ± 0.0081470 ± 0.0111500 ± 0.0061597 ± 0.0111498 ± 0.0111476 ± 0.018**1410** ± **0.014**[a](#tbl3fna){ref-type="table-fn"}1509 ± 0.0101585 ± 0.010[^6][^7][^8][^9][^10][^11]Table 4Morphometric callus parameters in 12-week-old vehicle- or LacCer-treated female C57BL/6 mice 10--21 days postosteotomy.Table 4TreatmentVehicleLacCerDay10 (7)12 (7)15 (7)18 (7)21 (7)10 (6)12 (7)15 (7)18 (7)21 (7)**TV** (mm^3^)9.11 ± 0.2311.19 ± 0.9811.41 ± 1.119.37 ± 0.529.38 ± 0.758.37 ± 0.7111.11 ± 0.8111.14 ± 1.397.65 ± 0.678.65 ± 0.91**BV** (mm^3^)2.31 ± 0.083.14 ± 0.293.08 ± 0.312.23 ± 0.161.90 ± 0.161.95 ± 0.243.03 ± 0.233.08 ± 0.361.82 ± 0.171.84 ± 0.19**BV/TV** (%)25.3 ± 0.428.0 ± 0.327.0 ± 0.323.8 ± 0.620.4 ± 0.823.0 ± 1.127.2 ± 0.327.8 ± 0.523.7 ± 0.721.2 ± 0.5**TS** (mm^2^)98.4 ± 1.8102.6 ± 6.4105.9 ± 5.395.2 ± 4.790.9 ± 3.391.3 ± 5.1101.9 ± 2.6102.1 ± 6.784.5 ± 3.685.9 ± 3.8**BS** (mm^2^)292.3 ± 9.3383.8 ± 37.7371.9 ± 38.8252.6 ± 19.9206.9 ± 17.5247.1 ± 29.9377.1 ± 29.2369.5 ± 48.0202.0 ± 20.0200.4 ± 20.4**iS** (mm^2^)11.6 ± 0.216.7 ± 0.822.4 ± 1.020.9 ± 1.120.3 ± 0.811.3 ± 0.916.1 ± 0.922.0 ± 1.119.3 ± 1.019.2 ± 0.7**TbPf** (mm^−1^)27.2 ± 0.623.7 ± 0.927.8 ± 0.729.9 ± 0.730.5 ± 0.728.8 ± 0.825.5 ± 0.825.9 ± 0.829.5 ± 0.730.3 ± 0.6**SMI** (unitless)1.29 ± 0.021.17 ± 0.041.39 ± 0.031.59 ± 0.041.68 ± 0.041.36 ± 0.031.23 ± 0.031.30 ± 0.041.60 ± 0.031.66 ± 0.03**Conn** (unitless)44681.1 ± 1512.158904.4 ± 6834.446689.0 ± 6146.622976.4 ± 2353.616062.7 ± 1662.835900.8 ± 5217.258732.4 ± 5054.248865.0 ± 9045.917408.6 ± 2083.615965.3 ± 1987.4**ConnDen** (μm^−1^)1.06 ± 0.021.12 ± 0.050.87 ± 0.040.53 ± 0.040.37 ± 0.030.91 ± 0.071.14 ± 0.030.92 ± 0.060.48 ± 0.020.39 ± 0.02**pMMI** (mm^4^)5.19 ± 0.286.66 ± 0.936.00 ± 0.833.83 ± 0.423.15 ± 0.364.08 ± 0.646.23 ± 0.635.86 ± 1.082.77 ± 0.352.91 ± 0.43**FD** (unitless)2.44 ± 0.012.51 ± 0.022.53 ± 0.022.48 ± 0.012.44 ± 0.012.41 ± 0.022.51 ± 0.022.54 ± 0.022.44 ± 0.022.43 ± 0.02**vBMD** (mg/mm^3^)1358 ± 0.0071386 ± 0.0171411 ± 0.0141477 ± 0.0061533 ± 0.007**1450 ± 0.029**[a](#tbl4fna){ref-type="table-fn"}1357 ± 0.0111404 ± 0.0141490 ± 0.0081.558 ± 0.012[^12][^13][^14][^15]

As illustrated in [Fig. 4](#fig4){ref-type="fig"}, both compounds showed greatest impact in bone mechanical properties on Day 18 postosteotomy. Again, this time point corresponds to peak endochondral mineralization and the beginning of the remodelling phases of healing. The effects of 24,25(OH)~2~D~3~ and LacCer were mainly evident in parameters such as stiffness ([Fig. 4](#fig4){ref-type="fig"}A and G) and elastic modulus ([Fig. 4](#fig4){ref-type="fig"}B and H). Interestingly, each compound had slightly different effects on some mechanical parameters: 24,25(OH)~2~D~3~ also significantly increased stiffness ([Fig. 4](#fig4){ref-type="fig"}A) and elastic modulus ([Fig. 4](#fig4){ref-type="fig"}B) on Day 10, whereas LacCer significantly enhanced load at yield ([Fig. 4](#fig4){ref-type="fig"}K) and strength at yield ([Fig. 4](#fig4){ref-type="fig"}L) on Day 18.Figure 4**Mechanical properties of calluses from C57BL/6 mice supplemented with 24,25(OH)~2~D~3~ or LacCer**. Twelve-week-old female mice were subcutaneously injected with 24,25(OH)~2~D~3~ (6,7 μg/kg; A--F), LacCer (50 μg/kg; G--L) or propylene glycol vehicle (50 μL) from 3 to 21 days post-OT. Parameters measured were bone stiffness (A and G), elastic modulus (B and H), maximum load (C and I), ultimate strength (D and J), load at yield (E and K) and strength at yield (F and L). ∗*p* \< 0.05; ∗∗*p* \< 0.01; ∗∗∗*p* \< 0.001 versus vehicle of corresponding time point; two-way ANOVA followed by Bonferroni post-test; number of mice per group indicated in parentheses above respective bar. Data are mean ± SEM. 24,25D~3~ = 24,25(OH)~2~D~3~; LacCer = lactosylceramide; OT = osteotomy; Veh = vehicle.Figure 4

Expression of TLCD3B during fracture repair {#sec3.5}
-------------------------------------------

Because the TLCD3B2 protein, the TLCD3B isoform most expressed in chondrocytes, has been demonstrated to be the effector protein binding 24,25(OH)~2~D~3~ and subsequently producing LacCer \[[@bib12]\], a TLCD3B global isoform antibody was used on undecalcified callus sections for each time point harvested ([Fig. 5](#fig5){ref-type="fig"}). TLCD3B2 was found to be expressed on Days 10 and 12 postosteotomy and to progressively recede to become undetectable by Day 18. TLCD3B2\'s presence in fracture callus seemed limited to the surface of unmineralized or pre-mineralized cartilage, respectively, visible as pink or purplish areas on the trichrome-stained sections (row A). By Day 18 postosteotomy, all that remained was nonspecific matrix binding of the secondary antibody.Figure 5**Expression of TLCD3B in callus tissue during fracture repair in C57BL/6 mice**. Top row: AB-OG-HE trichrome staining of undecalcified methylmethacrylate-embedded callus tissues harvested at Days (D) 10, 12, 15, 18 and 21 postosteotomy. Squares represent areas for fluorescent imaging and 4× zoom in rows B--D. Scale bar = 1 mm. Representative images from three samples per group. AB-OG-HE = Alcian Blue-Orange G-Hematoxylin.Figure 5

Because TLCD3B2 was most highly expressed on Days 10 and 12 postosteotomy, the effect of the 24,25(OH)~2~D~3~ or LacCer treatments on its expression was imaged ([Fig. 6](#fig6){ref-type="fig"}) and quantified ([Fig. 7](#fig7){ref-type="fig"}) at these time points. Both compounds at both time points reduced the number of TLCD3B2-positive cells ([Fig. 7](#fig7){ref-type="fig"}A and B). Again, as the cartilage mineralized (as illustrated by the blue areas in the trichrome-stained sections, Columns 1 and 4), the TLCD3B2 protein was restricted to the unmineralized or lightly mineralized areas of the callus (pinkish to purplish areas). The ratio of mineralized to unmineralized callus was significantly higher on Day 10 in 24,25(OH)~2~D~3~-treated calluses as well as on Days 10 and 12 in LacCer-treated calluses ([Fig. 7](#fig7){ref-type="fig"}C and D). Fully mineralized cartilage and bone tissue (in bright pink/pinkish orange, [Fig. 6](#fig6){ref-type="fig"}) did not express TLCD3B2. TLCD3B2 was not detected in treated samples on Days 15, 18 nor 21 (data not shown).Figure 6**Effect of 24,25(OH)~2~D~3~ or LacCer supplementation on TLCD3B expression in Days 10 and 12 callus tissue of C57BL/6 mice**. Columns 1 and 4: AB-OG-HE trichrome staining of undecalcified methylmethacrylate-embedded callus tissues harvested on Day 10 (D10, Columns 1--3) and Day 12 postosteotomy (D12, Columns 4--6) of vehicle- (row A), 24,25(OH)~2~D~3~- (row B) or LacCer- (row C) treated 12-week-old female mice. Scale bar = 1 mm. Columns 2 and 5: merged images of anti-TLCD3B (red) and DAPI (blue) of selected areas in Columns 1 and 4, respectively. Columns 3 and 6: 4× digital zoom of white square selected in images from Columns 2 and 5, respectively. Representative images from two (LacCer, D10) to three samples per group. AB-OG-HE = Alcian Blue-Orange G-Hematoxylin; LacCer = lactosylceramide.Figure 6Figure 7**Quantification of TLCD3B-positive cells and mineralized versus unmineralized area in Days 10 and 12 callus tissue from inbred mice supplemented with 24,25(OH)~2~D~3~ or LacCer**. Ratio of TLCD3B-positive cells per DAPI-stained in Day 10 (A) and Day 12 (B) postfracture callus tissue sections. Cells were counted with ImageJ within four regions of interest of 200 × 265 μm per image, for at least two images per sample, then averaged. ∗*p* \< 0.05; ∗∗*p* \< 0.01; ∗∗∗*p* \< 0.001, one-way ANOVA followed by Dunnett\'s post-test. Ratio of mineralized versus unmineralized cartilage in Day 10 (C) and Day 12 (D) callus tissue sections. Mineralized versus unmineralized callus tissue areas were measured with ImageJ within two regions of interest per sample comprising each half the callus, then averaged and expressed as a ratio. Three (Day 10) to four (Day 12) samples per group. 24,25D~3~ = 24,25(OH)~2~D~3~; LacCer = lactosylceramide; Veh = vehicle.Figure 7

Discussion {#sec4}
==========

The vitamin D metabolite, 24,25(OH)~2~D~3~, and LacCer were found to rescue callus formation in *Cyp24a1*-null mice \[[@bib12]\]. We aimed to assess their safety and efficacy in wild-type mice. A secondary objective was to determine which time range to consider for treatment.

Safety of 24,25(OH)~2~D~3~ or LacCer treatment in inbred, nongenetically modified mice {#sec4.1}
--------------------------------------------------------------------------------------

No toxicity of either 24,25(OH)~2~D~3~ or LacCer was observed, as ALT and AST levels were unaltered, and GGT levels remained below detectable threshold \[[@bib20]\]. The sustained low albumin and creatinine levels measured in all groups were likely caused by increased metabolic clearance \[[@bib21]\]. Because the same effect was observed in all groups, this might be linked to the propylene glycol vehicle, known to induce alcohol and lactate dehydrogenase and to increase urinary excretion in mammals \[[@bib22]\]. Another factor is the increased demand on kidney function caused by bone repair itself \[[@bib23]\]. Indeed, some studies suggest delayed fracture healing in experimental animals suffering kidney disease \[[@bib24]\], underscoring the importance of optimal kidney function during bone repair.

Wound healing in general increases metabolic demand in ATP \[[@bib15]\]. The present data supports this statement with higher serum levels of glucose---used by osteoblasts during aerobic glycolysis \[[@bib25]\]---and total ALP---increasing the amount of free inorganic phosphate \[[@bib26]\]. The latter may also reflect increased bone ALP during mineralization, agreeing with higher phosphorus levels necessary for hydroxyapatite formation \[[@bib27]\]. This observation is reinforced by the time point of increased ALP, specifically on Days 18 and 21. Although high ALP levels early on might reflect liver damage \[[@bib20]\], an absence of ALP increase would suggest no callus formation symptomatic of a nonunion \[[@bib28]\]. Although cFGF23 was reported to be a marker of bone fracture repair \[[@bib17]\], our data suggest that this hormone is not involved in mediating the effects of 24,25(OH)~2~D~3~ and LacCer.

Effect of fracture healing and treatment on vitamin D metabolism {#sec4.2}
----------------------------------------------------------------

As expected, subcutaneous injections of 24,25(OH)~2~D~3~ significantly increased circulating levels of 24,25(OH)~2~D~3~ and 1,24,25(OH)~3~D~3~. Interestingly, this treatment also significantly reduced levels of 1,25(OH)~2~D~3.~ Taken together, these data suggest that CYP27B1 used 24,25(OH)~2~D~3~ as a substrate for 1,24,25(OH)~3~D~3~ production instead of converting 25(OH)D~3~ into 1,25(OH)~2~D~3~. Indeed, competitive inhibition of 25(OH)D~3~ 1α-hydroxylation by high 24,25(OH)~2~D~3~ levels has been reported in calcium-deficient rats \[[@bib29]\], as well as in *Cyp24a1*-deficient mice \[[@bib13]\]. The LacCer-treated group showed no measurable difference in any of the vitamin D metabolites, suggesting little interaction with vitamin D metabolizing enzymes. The present data demonstrated that 24,25(OH)~2~D~3~ treatment had the most impact on vitamin D metabolism, illustrated by the loss of positive correlation between 25(OH)D~3~ and 24,25(OH)~2~D~3~ in the 24,25(OH)~2~D~3~-treated mice, where the rate of conversion is independent of the 25(OH)D~3~ metabolite from which it is derived. Treatment with 24,25(OH)~2~D~3~ probably also modulated CYP27B1 substrate selectivity, but this had no major impact on mineral ion homeostasis.

On the other hand, it was found that the fracture healing process systematically increased circulating levels of 25(OH)D~3~-26,23-lactone independently of treatment. This metabolite results from the C23-hydroxylation of 25(OH)D~3~ by the CYP24A1 enzyme \[[@bib30]\] and is largely thought to be inactive. However, some authors claim that the 26,23-lactone compounds of both 1,25(OH)~2~D~3~ and 25(OH)D~3~ increase intestinal calcium absorption and reduce bone calcium mobilization in chicks \[[@bib30]\]. Although these functions could be relevant in the context of fracture repair, no data exist in mammals as of yet. Moreover, our data indicate very stable serum calcium levels during the observed time range. Changes at later time points, beyond the endochondral ossification phase, cannot be excluded.

Efficacy of 24,25(OH)~2~D~3~ or LacCer in enhancing fracture repair in nongenetically modified mice {#sec4.3}
---------------------------------------------------------------------------------------------------

There is yet to be a consensus on the effect of vitamin D~3~ on bone healing \[[@bib8]\]. Indeed, beneficial effects of vitamin D~3~ supplementation during fracture repair mainly seems conclusive in cases of underlying deficiency or chronic kidney disease \[[@bib24]\] in mice. Time of intervention might also be a factor, as 1,25-dihydroxyvitamin D~3~ supplementation in normal mice during the inflammatory phase impairs bone healing by promoting M2 macrophage differentiation and inhibiting precursor cell migration at the wound site \[[@bib31]\]. Interestingly, a decrease in serum levels of 1,25-dihydroxyvitamin D~3~ postfracture has been reported in humans \[[@bib11]\]. Whether these effects are solely dependent on direct vitamin D receptor (VDR) targets or also secondary to CYP24A1*-*induced 24-hydroxylation remains undetermined.

Bone resorption, as evaluated by measuring levels of the CTX biomarker, was unaffected by either treatment. The OCN bone formation marker was found to be significantly reduced on Day 18 of 24,25(OH)~2~D~3~ treatment. This might be related to the fact that during fracture repair, OCN is mainly expressed in the unmineralized to mineralized transition zone of the callus, which disappears during the remodelling phase \[[@bib32]\].

Both 24,25(OH)~2~D~3~ and LacCer significantly ameliorated mechanical outcome of the callus during healing. Both compounds enhanced callus formation during the endochondral phase. We have reported that chondrogenic ATDC5 cells stably overexpressing *Tlcd3b2* showed elevated type 2 (*Col2a1*) and type 10 (*Col10a1*) collagen gene expression and increased proteoglycan synthesis \[[@bib33]\]. Treatment of *Tlcd3b2*-overexpressing ATDC5 cells with 24,25(OH)~2~D~3~ further increased the expression of *Col2a1*. Treatment of untransfected ATDC5 cells with LacCer enhanced chondrocyte maturation \[[@bib33]\]. Overall, results from these studies strongly support a role for TLCD3B2 and LacCer in chondrocyte maturation and confirm the hypothesis that TLCD3B2 is involved in the endochondral stage of bone fracture healing by optimizing the maturation and potentially the hypertrophy of chondrocytes.

Moreover, recent work from van der Meijden et al. \[[@bib34]\] demonstrated that primary human osteoblasts actively synthesize 24,25(OH)~2~D~3~ *in vitro*, which increases ALP, OCN and osteopontin mRNA \[[@bib34]\], suggesting a role in osteoblast biomineralization. Microvesicles are known to be the site of hydroxyapatite nucleation during biomineralization \[[@bib35]\]. Microvesicles are shed from lipid rafts, plasma membrane microdomains enriched in cholesterol, sphingomyelin and LacCer \[[@bib35]\]. Thus, perhaps 24,25(OH)~2~D~3~ stimulates biomineralization during fracture repair by a dual mechanism: through the induction of matrix mineralizing protein expression and through the LacCer-producing activity of TLCD3B2.

We did not perform direct comparison of the effects of 24,25(OH)~2~D~3~ and LacCer with known bone anabolic agents. Recombinant BMP-2 has been tested for the treatment of fresh, open tibial fractures but a double-blind, randomized controlled trial concluded that the times to fracture union were not substantially reduced by BMP-2 treatment \[[@bib36]\]. Treatment with PTH has also been shown to be efficacious for fracture repair in postmenopausal women \[[@bib37]\]. However, the FDA recommends against treatment with PTH (teriparatide) for children and adolescents whose bones are still growing. Thus, our preclinical results could be translated into a therapeutic modality for a juvenile population, such as patients with osteogenesis imperfecta \[[@bib38]\].

Time range for most efficient treatment {#sec4.4}
---------------------------------------

Bone fracture repair essentially recapitulates embryonic bone formation \[[@bib5]\]. The soft callus is a transient cartilage anlage, formed through mesenchymal condensation, undergoing hypertrophy, calcification and remodelling into lamellar bone, tightly regulated by numerous internal and external cues \[[@bib6]\]. The callus being avascular, it remains debated how circulating compounds might reach the wound site. It has long been suspected that lipids play a significant role at this level as they facilitate passive diffusion before vascularization takes place \[[@bib39]\] and participate to the formation of calcium hydroxyapatite crystals \[[@bib40]\]. Indeed, matrix vesicles---enriched in cholesterol, phospholipids and glycolipids \[[@bib35]\]---are the site of hydroxyapatite nucleation \[[@bib26]\].

Although the strongest effect for both treatments manifested on Day 18, the present data demonstrate that expression of the TLCD3B2 effector protein is highest 10--12 days postosteotomy. Moreover, downregulation of the protein by either compound was most obvious at these time points, suggesting efficient targeting of the callus tissue before the onset of mineralization. The decrease in TLCD3B2 protein expression mimics the reduction in *Tlcd3b2* expression after treatment with 24,25(OH)~2~D~3~ that we previously reported in the fracture callus and cultured chondrocytes \[[@bib12]\]. The time lag between TLCD3B2 peak expression and maximal mechanical properties is probably due to the cell proliferation, differentiation and mineralization periods necessary for endochondral ossification \[[@bib6]\]. Our data suggest that 24,25(OH)~2~D~3~ or LacCer administration should occur before initiation of callus mineralization, during peak TLCD3B2 expression. This seems particularly relevant for 24,25(OH)~2~D~3~ supplementation as stiffness and elastic modulus were both increased on Day 10 postosteotomy.

Conclusion {#sec5}
==========

The present data demonstrate that both 24,25(OH)~2~D~3~ and LacCer significantly increase mechanical properties of the callus in wild-type, nongenetically modified mice. Neither compound was found to exhibit any nephro- nor hepato-toxicity. However, the 24,25(OH)~2~D~3~ treatment did show significant impact on vitamin D metabolism, namely higher levels of 24,25(OH)~2~D~3~ and 1,24,25(OH)~3~D~3~, as well as lower levels of 1,25(OH)~2~D~3~. These effects are a direct consequence of the administration of the compound, which remains safe because calcaemia was not affected in the least. As 24,25(OH)~2~D~3~ impacted both callus structure and mechanical properties, it seems to have a broader range of activity than LacCer, which only influenced mechanical properties.
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[^1]: Parameters are followed by mice normal range values and/or units in parentheses. Data are mean ± SEM, *n* = 6 mice/group except for OCN and CTX where *n* = 5 mice/group. Bold signifies statistically significant change vs. vehicle.

[^2]: AGR = albumin-to-globulin ratio; ALT = alanine transaminase; ANOVA = analysis of variance; AST = aspartate transaminase; BUN = blood urea nitrogen; CK = creatine kinase; CTX = carboxy-terminal collagen crosslinks; GGT = gamma-glutamyl transferase; NA = not available; OCN = osteocalcin; SEM = standard error of the mean; Tot. bil. = total bilirubin.

[^3]: *p* \< 0.01 versus vehicle of corresponding time point, two-way ANOVA followed by Bonferroni post-test.

[^4]: Parameters are followed by mice normal range values and/or units in parentheses. Data are mean ± SEM, *n* = 6 mice/group except for OCN and CTX where *n* = 5 mice/group.

[^5]: AGR = albumin-to-globulin ratio; BUN: blood urea nitrogen; Tot. bil.: total bilirubin; ALT: alanine transaminase; AST: aspartate transaminase; GGT: gamma-glutamyl transferase; LacCer = lactosylceramide; CK: creatine kinase; OCN: osteocalcin; CTX, carboxy-terminal collagen crosslinks; NA, not available; SEM = standard error of the mean.

[^6]: Each parameter is followed by units in parentheses; number of mice per group indicated in parentheses at top of each column. Significant differences observed on Day 15 in treated groups versus vehicle for BV, BS, Conn, ConnDen, pMMI and vBMD. Bold signifies statistically significant change vs. vehicle.

[^7]: two-way ANOVA followed by Bonferroni post-test.

[^8]: ANOVA = analysis of variance; BS = bone surface; BV = bone volume; BV/TV = mineralized tissue fraction; Conn = connectivity; ConnDen = connectivity density; FD = fractal dimension; iS = intersection surface; pMMI = mean polar moment of inertia; SMI = structure model index; TbPf = trabecular pattern factor; TS = tissue surface; TV = tissue volume; vBMD = volumetric bone mineral density.

[^9]: *p* \< 0.05

[^10]: *p* \< 0.01

[^11]: *p* \< 0.001

[^12]: Each parameter is followed by units in parentheses; number of mice per group indicated in parentheses at top of each column. Statistically significant differences were observed on Day 10 in treated group versus vehicle for vBMD;

[^13]: two-way ANOVA followed by Bonferroni post-test. Bold signifies statistically significant change vs. vehicle.

[^14]: ANOVA = analysis of variance; BS = bone surface; BV = bone volume; BV/TV = mineralized tissue fraction; Conn = connectivity; ConnDen = connectivity density; FD = fractal dimension; iS = intersection surface; pMMI = mean polar moment of inertia; SMI = structure model index; TbPf = trabecular pattern factor; TS = tissue surface; TV = tissue volume; vBMD = volumetric bone mineral density.

[^15]: *p* \< 0.001
